Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
solid tumor
Biotech
Aadi buys preclinical ADCs, sells Fyarro to reboot business
Aadi is transforming from a commercial business into a preclinical biotech by offloading its approved product and licensing ADCs for $44 million.
Nick Paul Taylor
Dec 20, 2024 3:54am
BeiGene inks $150M deal to follow cancer trail blazed by Amgen
Dec 13, 2024 9:11am
Elevation lifts HER3 ADC toward clinic with $368M Synaffix deal
Dec 12, 2024 9:19am
Chasing Merck, BioNTech, DualityBio post first data on ADC
Dec 6, 2024 9:07am
Gilead advances ADC dreams with potential $465M deal
Dec 3, 2024 10:54am
Ipsen taps Biomunex's MAITs to treat solid tumors in $610M bet
Dec 3, 2024 6:00am
